Stephen Archer to Hypertension, Pulmonary
This is a "connection" page, showing publications Stephen Archer has written about Hypertension, Pulmonary.
Connection Strength
20.684
-
Novel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension. Hypertension. 2024 Oct; 81(10):2189-2201.
Score: 0.649
-
Complete Revascularization of the Pulmonary Circulation in Chronic Thromboembolic Pulmonary Hypertension: Value of Addressing Chronic Total Occlusions. Can J Cardiol. 2024 04; 40(4):634-636.
Score: 0.617
-
Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer. Free Radic Biol Med. 2021 07; 170:150-178.
Score: 0.506
-
Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema: Therapeutic Implications. Circulation. 2020 07 14; 142(2):101-104.
Score: 0.482
-
Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis. Circ Res. 2020 06 05; 126(12):1723-1745.
Score: 0.478
-
Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. Circ Res. 2019 08 02; 125(4):449-466.
Score: 0.452
-
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. J Am Heart Assoc. 2019 01 08; 8(1):e011343.
Score: 0.440
-
Transcriptomic Signature of Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension: Deep Sequencing Demonstrates Mitochondrial, Fibrotic, Inflammatory and Angiogenic Abnormalities. Int J Mol Sci. 2018 Sep 12; 19(9).
Score: 0.430
-
A Step Closer to Understanding How Riociguat Results in Remodelling of the Right Ventricle in Chronic Thromboembolic Pulmonary Hypertension. Can J Cardiol. 2018 09; 34(9):1098-1101.
Score: 0.426
-
Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018 03 14; 360:j5492.
Score: 0.415
-
Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018 02; 11(2):e003973.
Score: 0.412
-
Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension: Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary Arterial Hypertension. Circulation. 2017 12 19; 136(25):2486-2490.
Score: 0.409
-
Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. Hypertension. 2018 01; 71(1):34-55.
Score: 0.407
-
Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension. J Am Heart Assoc. 2017 May 31; 6(6).
Score: 0.393
-
Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension. J Mol Med (Berl). 2017 04; 95(4):381-393.
Score: 0.387
-
MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. Am J Respir Crit Care Med. 2017 Feb 15; 195(4):515-529.
Score: 0.386
-
Pulmonary hypertension begets pulmonary hypertension: mutually reinforcing roles for haemodynamics, inflammation, and cancer-like phenotypes. Cardiovasc Res. 2016 07 01; 111(1):1-4.
Score: 0.367
-
Acquired Mitochondrial Abnormalities, Including Epigenetic Inhibition of Superoxide Dismutase 2, in Pulmonary Hypertension and Cancer: Therapeutic Implications. Adv Exp Med Biol. 2016; 903:29-53.
Score: 0.357
-
Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation. 2015 May 12; 131(19):1691-702.
Score: 0.341
-
Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med (Berl). 2015 Mar; 93(3):229-42.
Score: 0.336
-
Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol. 2015 Apr; 31(4):391-406.
Score: 0.335
-
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther. 2015 Jan; 97(1):88-102.
Score: 0.331
-
The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014 Jun 20; 115(1):176-88.
Score: 0.321
-
Riociguat for pulmonary hypertension--a glass half full. N Engl J Med. 2013 Jul 25; 369(4):386-8.
Score: 0.301
-
PGC1a-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):865-78.
Score: 0.296
-
Rodent models of group 1 pulmonary hypertension. Handb Exp Pharmacol. 2013; 218:105-49.
Score: 0.290
-
GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation. 2012 Dec 11; 126(24):2859-69.
Score: 0.287
-
Evolving epidemiology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Oct 15; 186(8):707-9.
Score: 0.286
-
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012 May 25; 110(11):1484-97.
Score: 0.276
-
QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 2013 Aug 10; 167(3):669-76.
Score: 0.275
-
Lung ยน8F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):670-9.
Score: 0.271
-
Pulmonary endarterectomy surgery--a technically demanding cure for WHO Group IV Pulmonary Hypertension: requirements for centres of excellence and availability in Canada. Can J Cardiol. 2011 Nov-Dec; 27(6):671-4.
Score: 0.267
-
Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl. 2011 Aug; (172):15-34.
Score: 0.263
-
Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010 Nov; 138(5):1234-9.
Score: 0.249
-
Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2010 Sep; 299(3):L401-12.
Score: 0.243
-
Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010 Jun 22; 121(24):2661-71.
Score: 0.243
-
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010 May 11; 121(18):2045-66.
Score: 0.241
-
Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep. 2010 Feb; 12(1):8-18.
Score: 0.237
-
A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol. 2010; 661:171-85.
Score: 0.235
-
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009 Nov 05; 361(19):1864-71.
Score: 0.233
-
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol. 2008 Feb; 294(2):H570-8.
Score: 0.204
-
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol. 2007 Oct; 293(4):L933-40.
Score: 0.199
-
Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther. 2007 Jul; 115(1):56-69.
Score: 0.195
-
The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation. 2006 Dec; 13(8):615-32.
Score: 0.190
-
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007 Apr; 292(4):L872-8.
Score: 0.190
-
An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol. 2006 Jul; 21(4):385-92.
Score: 0.185
-
Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985). 2005 Jan; 98(1):390-403.
Score: 0.166
-
Pulmonary hypertension. Nat Rev Dis Primers. 2024 Jan 04; 10(1):1.
Score: 0.155
-
Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003 Oct 28; 108(17):2066-9.
Score: 0.153
-
Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension. J Am Heart Assoc. 2023 03 21; 12(6):e027559.
Score: 0.147
-
The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. Adv Exp Med Biol. 2003; 543:293-322.
Score: 0.145
-
Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2022 09 01; 206(5):608-624.
Score: 0.142
-
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002 May 21; 105(20):2398-403.
Score: 0.139
-
Inhibiting pyruvate kinase muscle isoform 2 regresses group 2 pulmonary hypertension induced by supra-coronary aortic banding. Acta Physiol (Oxf). 2022 02; 234(2):e13764.
Score: 0.136
-
Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002 Jan 15; 105(2):244-50.
Score: 0.136
-
PINK1-induced phosphorylation of mitofusin 2 at serine 442 causes its proteasomal degradation and promotes cell proliferation in lung cancer and pulmonary arterial hypertension. FASEB J. 2021 08; 35(8):e21771.
Score: 0.131
-
Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circ Heart Fail. 2021 06; 14(6).
Score: 0.130
-
Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Increasing expression and activity of potassium channels in rat and human models. Adv Exp Med Biol. 2001; 502:401-18.
Score: 0.126
-
Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation. 2000 Nov 28; 102(22):2781-91.
Score: 0.125
-
Mitochondria in the Pulmonary Vasculature in Health and Disease: Oxygen-Sensing, Metabolism, and Dynamics. Compr Physiol. 2020 03 12; 10(2):713-765.
Score: 0.119
-
Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease. J Am Heart Assoc. 2019 01 22; 8(2):e011464.
Score: 0.110
-
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat. J Vis Exp. 2018 11 18; (141).
Score: 0.109
-
Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998 Oct; 158(4):1061-7.
Score: 0.108
-
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. J Heart Lung Transplant. 2019 02; 38(2):145-155.
Score: 0.108
-
A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. Chest. 1998 Sep; 114(3 Suppl):200S-204S.
Score: 0.107
-
Pulmonary vasoconstriction, oxygen sensing, and the role of ion channels: Thomas A. Neff lecture. Chest. 1998 Jul; 114(1 Suppl):17S-22S.
Score: 0.106
-
A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017. Am J Physiol Lung Cell Mol Physiol. 2018 10 01; 315(4):L502-L516.
Score: 0.106
-
Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. Am J Respir Crit Care Med. 2018 06 01; 197(11):1496-1499.
Score: 0.105
-
Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circ Res. 2018 03 30; 122(7):1021-1032.
Score: 0.104
-
Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications. Circulation. 2018 07 17; 138(3):287-304.
Score: 0.103
-
Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant. 2018 03; 37(3):376-384.
Score: 0.100
-
Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2016 08 15; 194(4):464-75.
Score: 0.093
-
Chronic infusion of nitric oxide in experimental pulmonary hypertension: pulmonary pressure-flow analysis. Eur Respir J. 1996 Jul; 9(7):1475-81.
Score: 0.092
-
Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc Res. 1996 Jan; 31(1):55-62.
Score: 0.089
-
Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24; 132(21):2037-99.
Score: 0.088
-
Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 2015 Jan 27; 131(4):401-9; discussion 409.
Score: 0.082
-
An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. 2014 Feb 01; 189(3):345-55.
Score: 0.078
-
Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D4-12.
Score: 0.078
-
Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med (Berl). 2013 Oct; 91(10):1185-97.
Score: 0.075
-
FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl). 2013 Mar; 91(3):333-46.
Score: 0.072
-
Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur Respir J. 2013 Jul; 42(1):125-33.
Score: 0.072
-
Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology. 2012 Oct; 61(4):597-609.
Score: 0.071
-
Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012 Feb 01; 14:11.
Score: 0.068
-
Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia. Circulation. 2011 May 17; 123(19):2120-31.
Score: 0.065
-
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011 Apr 26; 123(16):1788-830.
Score: 0.064
-
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010 May; 35(5):1079-87.
Score: 0.059
-
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010 Mar; 87(3):303-10.
Score: 0.059
-
Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2):181-7.
Score: 0.058
-
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S20-S31.
Score: 0.057
-
Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail. 2009 Jul; 2(4):278-86.
Score: 0.056
-
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619.
Score: 0.056
-
Effect of dietary fish oil on lung lipid profile and hypoxic pulmonary hypertension. J Appl Physiol (1985). 1989 Apr; 66(4):1662-73.
Score: 0.056
-
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94.
Score: 0.056
-
Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation. 2008 May 13; 117(19):2475-83.
Score: 0.052
-
The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11418-23.
Score: 0.049
-
ZK 36-374, a stable analog of prostacyclin, prevents acute hypoxic pulmonary hypertension in the dog. J Am Coll Cardiol. 1986 Nov; 8(5):1189-94.
Score: 0.047
-
An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006 Jun 06; 113(22):2630-41.
Score: 0.046
-
Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Can J Cardiol. 2005 Sep; 21(11):909-14.
Score: 0.044
-
Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Can Respir J. 2005 Sep; 12(6):303-15.
Score: 0.044
-
Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005 Jun; 115(6):1479-91.
Score: 0.043
-
Comparative effects of nisoldipine, nifedipine and bepridil on experimental pulmonary hypertension. J Pharmacol Exp Ther. 1985 Apr; 233(1):12-7.
Score: 0.042
-
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004 Jun 22; 109(24):2947-52.
Score: 0.040
-
Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):13S-24S.
Score: 0.040
-
In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 2003 Apr 22; 107(15):2037-44.
Score: 0.037
-
Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility. Circ Heart Fail. 2022 01; 15(1):e008574.
Score: 0.034
-
Aerosol delivery of diethylenetriamine/nitric oxide, a nitric oxide adduct, causes selective pulmonary vasodilation in perinatal lambs. J Lab Clin Med. 1999 Oct; 134(4):419-25.
Score: 0.029
-
Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996 Nov 01; 94(9):2216-20.
Score: 0.024
-
The somatostatin analog angiopeptin does not reduce chronic hypoxic pulmonary hypertension in rats. Proc Soc Exp Biol Med. 1996 Oct; 213(1):43-9.
Score: 0.023
-
A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest. 1996 Mar; 109(3):750-5.
Score: 0.023
-
Chronic hypoxic pulmonary hypertension. Is thrombin involved? Am Rev Respir Dis. 1993 Oct; 148(4 Pt 1):1043-8.
Score: 0.019
-
Comparison of the hemodynamic effects of nitric oxide and endothelium-dependent vasodilators in intact lungs. J Appl Physiol (1985). 1990 Feb; 68(2):735-47.
Score: 0.015
-
Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009 Dec 01; 180(11):1131-42.
Score: 0.014
-
Chronic primary and secondary thromboembolic pulmonary hypertension. Chest. 1988 Mar; 93(3 Suppl):149S-154S.
Score: 0.013
-
Acute oxygen-sensing mechanisms. N Engl J Med. 2005 Nov 10; 353(19):2042-55.
Score: 0.011
-
Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol (1985). 1993 Oct; 75(4):1748-57.
Score: 0.005